Cell Therapy

News

Repligen builds in cell therapy with $1.5bn BioLife takeover

Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.

News

Cellular Intelligence scoops up Novo's Parkinson's therapy

Novo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit to AI start-up Cellular Intelligence.

News

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

R&D

Allogeneic cell therapy isn’t dead, with Brian Culley

Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone

News

Galapagos abandons cell therapy, putting 365 jobs at risk

Galapagos' difficult year has continued with a decision to wind down its cell therapy business as it seeks 'transformative' deals for its drugs unit.

Repligen builds in cell therapy with $1.5bn BioLife takeover

Cellular Intelligence scoops up Novo's Parkinson's therapy

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

Allogeneic cell therapy isn’t dead, with Brian Culley

Engineering “smarter” cells, with Tim Lu

Galapagos abandons cell therapy, putting 365 jobs at risk

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

Cell Therapy

Editor's Picks